GlassScriptPhysician profile
Seth H Greenberg
NPI 1467552497
$7,659.10
in general payments reported to CMS, 2019-2025
44 companies · $622 in 2025
The $622 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,482 · 2020: $772 · 2021: $1,018 · 2022: $1,407 · 2023: $1,567 · 2024: $793 · 2025: $622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,981.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,199.21 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,081.73 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Genzyme Corporation | $439.11 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $417.75 | 2020-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $407.07 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Inspire Medical Systems, INC. | $349.26 | 2023-2025 | Inspire |
| Genentech USA, INC. | $344.91 | 2019-2024 | Xolair |
| Actelion Pharmaceuticals US, INC. | $322.13 | 2019-2023 | Uptravi |
| Jazz Pharmaceuticals INC. | $267.11 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $208.76 | 2019-2025 | Dupixent |
| Amgen INC. | $194.66 | 2022-2025 | Tezspire |
| Sunovion Pharmaceuticals INC. | $185.91 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $180.14 | 2022-2024 | Glassia, Cuvitru |
| Advanced Respiratory, INC | $166.23 | 2019-2021 | |
| Insmed, INC. | $162.42 | 2019-2023 | Arikayce |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $160.81 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $139.86 | 2023-2024 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $124.54 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $123.27 | 2019-2023 | Xarelto |
| Philips North America LLC | $100.58 | 2019-2025 | Vest Therapy Und |
| United Therapeutics Corporation | $96.86 | 2021-2023 | Tyvaso |
| Pharming Healthcare, INC. | $90.41 | 2022-2023 | Ruconest |
| Paratek Pharmaceuticals, INC. | $84.37 | 2021-2023 | Nuzyra |
| Pfizer INC. | $83.18 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $77.12 | 2023-2024 | Winrevair |
| Baxter Healthcare | $71.57 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| Mylan Specialty L.P. | $69.21 | 2019-2023 | Yupelri |
| Harmony Biosciences LLC | $64.16 | 2022-2023 | Wakix |
| Pulmonx Corporation | $54.25 | 2023-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Verona Pharma, INC. | $50.98 | 2025 | Ohtuvayre |
| Mallinckrodt Enterprises LLC | $45.56 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $41.08 | 2021-2022 | |
| Resmed Corp | $29.48 | 2019 | |
| Vifor Pharma, INC. | $29.22 | 2024 | Veltassa |
| Axsome Therapeutics, INC. | $28.97 | 2023 | Sunosi |
| Lilly USA, LLC | $27.95 | 2025 | Zepbound |
| Inari Medical, INC. | $26.04 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Inogen, INC. | $25.52 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Shionogi INC | $22.54 | 2023 | Fetroja |
| Nabriva Therapeutics, Plc | $16.58 | 2021 | |
| Electromed, INC. | $12.53 | 2021 | |
| Gilead Sciences, INC. | $12.31 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.23 | 2019 | |
| Tactile Systems Technology INC | $11.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Greenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.